PDE3A

phosphodiesterase 3A, the group of Phosphodiesterases

Basic information

Region (hg38): 12:20368537-20688583

Links

ENSG00000172572NCBI:5139OMIM:123805HGNC:8778Uniprot:Q14432AlphaFoldGenCCjaxSfariGnomADPubmedClinVar

Phenotypes

GenCC

Source: genCC

  • brachydactyly-arterial hypertension syndrome (Strong), mode of inheritance: AD
  • brachydactyly-arterial hypertension syndrome (Supportive), mode of inheritance: AD

Clinical Genomic Database

Source: CGD

ConditionInheritanceIntervention CategoriesIntervention/Rationale Manifestation CategoriesReferences
Hypertension with brachydactyly syndromeADCardiovascularIndividuals have been described as suffering from death by stroke by age 50 when untreated, and awareness may allow early management of hypertension, which has been described as having onset in childhoodCardiovascular; Musculoskeletal4774535; 9415685; 25961942

ClinVar

This is a list of variants' phenotypes submitted to ClinVar and linked to the PDE3A gene.

  • not_provided (136 variants)
  • Inborn_genetic_diseases (127 variants)
  • Brachydactyly-arterial_hypertension_syndrome (24 variants)
  • PDE3A-related_disorder (20 variants)
  • not_specified (6 variants)
  • Prostate_cancer (1 variants)
  • VATER_association (1 variants)
  • Intellectual_disability (1 variants)

Variants pathogenicity by type

Statistics on ClinVar variants can assist in determining whether a specific variant type in the PDE3A gene is commonly pathogenic or not. These statistics are base on transcript: NM_000000921.5. Only rare variants are included in the table.

In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.

Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.

EffectPLPVUSLBBSum
synonymous
2
clinvar
33
clinvar
16
clinvar
51
missense
7
clinvar
1
clinvar
180
clinvar
17
clinvar
3
clinvar
208
nonsense
4
clinvar
4
start loss
0
frameshift
1
clinvar
1
splice donor/acceptor (+/-2bp)
1
clinvar
1
Total 7 1 188 50 19
Loading clinvar variants...

GnomAD

Source: gnomAD

GeneTypeBio TypeTranscript Coding Exons Length
PDE3Aprotein_codingprotein_codingENST00000359062 16315137
pLI Probability
LOF Intolerant
pRec Probability
LOF Recessive
Individuals with
no LOFs
Individuals with
Homozygous LOFs
Individuals with
Heterozygous LOFs
Defined p
0.0001931.001256840641257480.000255
Z-Score Observed Expected Observed/Expected Mutation Rate Total Possible in Transcript
Missense0.5925866280.9330.00003137379
Missense in Polyphen121202.590.597252297
Synonymous-2.002962551.160.00001352322
Loss of Function4.131544.80.3350.00000207555

LoF frequencies by population

EthnicitySum of pLOFs p
African & African-American0.0008940.000858
Ashkenazi Jewish0.000.00
East Asian0.0006600.000598
Finnish0.00009780.0000924
European (Non-Finnish)0.0002450.000229
Middle Eastern0.0006600.000598
South Asian0.0002630.000261
Other0.0003330.000326

dbNSFP

Source: dbNSFP

Function
FUNCTION: Cyclic nucleotide phosphodiesterase with a dual- specificity for the second messengers cAMP and cGMP, which are key regulators of many important physiological processes. {ECO:0000250|UniProtKB:Q9Z0X4}.;
Disease
DISEASE: Hypertension and brachydactyly syndrome (HTNB) [MIM:112410]: A syndrome characterized by brachydactyly type E, severe salt-independent but age-dependent hypertension, an increased fibroblast growth rate, neurovascular contact at the rostral-ventrolateral medulla, and altered baroreflex blood pressure regulation. It results in death from stroke before age 50 years when untreated. Brachydactyly type E is characterized by shortening of the fingers mainly in the metacarpals and metatarsals. {ECO:0000269|PubMed:25961942}. Note=The disease is caused by mutations affecting the gene represented in this entry.;
Pathway
cAMP signaling pathway - Homo sapiens (human);Renin secretion - Homo sapiens (human);Purine metabolism - Homo sapiens (human);cGMP-PKG signaling pathway - Homo sapiens (human);Morphine addiction - Homo sapiens (human);Proton Pump Inhibitor Pathway, Pharmacodynamics;miR-targeted genes in lymphocytes - TarBase;miR-targeted genes in muscle cell - TarBase;NO-cGMP-PKG mediated Neuroprotection;Phosphodiesterases in neuronal function;Signaling by GPCR;Signal Transduction;G alpha (s) signalling events;actions of nitric oxide in the heart;Purine nucleotides nucleosides metabolism;Hemostasis;Leptin;cGMP effects;Nitric oxide stimulates guanylate cyclase;Platelet homeostasis;GPCR downstream signalling (Consensus)

Recessive Scores

pRec
0.147

Intolerance Scores

loftool
0.399
rvis_EVS
-1.1
rvis_percentile_EVS
6.89

Haploinsufficiency Scores

pHI
0.0948
hipred
Y
hipred_score
0.746
ghis
0.526

Essentials

essential_gene_CRISPR
N
essential_gene_CRISPR2
N
essential_gene_gene_trap
N
gene_indispensability_pred
E
gene_indispensability_score
0.956

Gene Damage Prediction

AllRecessiveDominant
MendelianMediumMediumMedium
Primary ImmunodeficiencyMediumMediumMedium
CancerMediumMediumMedium

Mouse Genome Informatics

Gene name
Pde3a
Phenotype
normal phenotype; reproductive system phenotype;

Gene ontology

Biological process
oocyte maturation;lipid metabolic process;G protein-coupled receptor signaling pathway;cAMP-mediated signaling;cGMP-mediated signaling;regulation of meiotic nuclear division;response to drug;negative regulation of apoptotic process;negative regulation of vascular permeability;positive regulation of vascular permeability;negative regulation of cAMP-mediated signaling;positive regulation of oocyte development;cellular response to cGMP;cellular response to transforming growth factor beta stimulus
Cellular component
cytosol;integral component of membrane
Molecular function
3',5'-cyclic-AMP phosphodiesterase activity;cGMP-inhibited cyclic-nucleotide phosphodiesterase activity;protein binding;metal ion binding;3',5'-cyclic-GMP phosphodiesterase activity